Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TheraBionic P1 Device for Patients With Advanced Hepatocellular Carcinoma (HCC) Who Fail First and Second Line Therapy

NCT07118202 is registered in ClinicalTrials.gov with Barbara Ann Karmanos Cancer Institute as lead sponsor.

NCT NCT07118202
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07118202 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TheraBionic P1 Device for Patients With Advanced Hepatocellular Carcinoma (HCC) Who Fail First and Second Line Therapy
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Phase
Not applicable
Overall status
Recruiting
Start date
October 20, 2025
Completion date
August 31, 2028
Enrollment
198 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma recurrent